#EULAR2020 #LB0001 SELECT-PsA-1 Upadacitinib vs PBO vs ADA: UPA 15/30 mg non-inferior &UPA 30 superior to ADA for ACR20. At wk12 ACR 20 70.6% UPA15, 78.5% UPA30 vs 36.2%PBO & 65%ADA. Better ACR50/70 &MDA va PBO. No new safety signals. @RheumNow https://t.co/QZkMdoqXEC

#eular2020 #op0205 phase 1 trial of novel URAT1 inhibitor D-0120 in healthy adults: safe up to 20 mg/d after 7 days. Significant reduction of sUA peaks at 4-8h & lasts up to 24h @RheumNow

#EULAR2020 #op0106 Cosentyx 150mg demonstrates clinical improvement in NrAxSpA Sx in Ph3 PREVENT 52wk study. Significant improvement in ASAS40, BASDAI50& ASdAS-CRP ID. MRI BME score significantly decreased (-1.68&-1.03 (no LD) vs -0.39 PBO) @RheumNow https://t.co/UX7mkJ8qMJ

#eular2020 #op0227 52 wk SEC vs ADA H2H EXCEED trial: Acr20 67.4%SEC vs 61.5%ADA. Better retention of SEC at 85.7% vs 76.3%ADA. SEC significantly outperforms in PASI90 (65.4 SEC be 43.2 ADA) @RheumNow https://t.co/M8UGydTFDF

EULAR2020 #op0168 🇰🇷Population-based cohort study identifies both allopurinol& febuxostat associated with MI, cerebral infarction&cerebral hemorrhage. Fluctuation of sUA&potentially even cardiovascular gout attacks (urate crystals in vasculature) as possible causes @RheumNow https://t.co/mcb5NLnMq1

#EULAR2020 #op0028 12 wk ph3 RELIEF study: Apremilast effectively relieves OU pain and OU number after 12 wks of 30 mg bid Rx. Great proportion of APR PTs achieved >10 mm &>30 mm improvement in OU pain @RheumNow https://t.co/p71sz9XL0e

Lots of talk about best bDMARDs in RA-ILD, but what about in RA-assoc bronchiectasis? @Yuz6Yusof found rituximab had better 'lung survival' vs TNFi (similar baseline stats) Something to consider in these difficult-to-treat pts? @LeedsBRC Newcastle THU0143 #EULAR2020 @RheumNow https://t.co/XpffkDNqhU

For patients on bDMARDs having surgery, we worry about post-op delayed wound healing. In this Japanese cohort, TCZ use was a risk factor. Unclear if meds withheld, but given IL-6 upreg in wound healing, it's plausible TCZ might have worse outcomes?? SAT0047 #EULAR2020 @RheumNow https://t.co/HVIKPplwiA

So maybe the optimal dose for psoriasis with UPA in PsA was tested? UPA works in PsA so another potential Rx for pts LB0001 @eular_org #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/GiT7H91umA

• https://twitter.com/drpnash/status/1268384558719762432

Whom with GCA should receive tocilizumab? What happens when it is stopped? Optimal dose for maintenance weekly or Q2 weekly? GiACTA gives only some answers. Need RWE #EULAR2020 @eular_org @RheumNow @CRASCRRheum @earlyarthritis #vasculitis https://t.co/aNvR14vfEV

• https://twitter.com/drdavidliew/status/1268201330914385921

What dose/frequency of rituximab do you use in maintenance ANCA #vasculitis? @RheumNow @eular_org @CRASCRRheum @earlyarthritis #EULAR2020

Hand OA Rx strikes out. HCQ Rx neg and colchicine Trial negative. I wouldn’t put hand OA as same category of no Rx as for SSc and Sjogrens but agree though nuts to crack @eular_org @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/QRe3UpKpbz

• https://twitter.com/rheumnow/status/1269051282238701569

Awesome colchicine data from @CatherineL_Hill @samwhittle and others: Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH) Abstract FRI0399 #EULAR2020 @RheumNow https://t.co/NVw9fo55dc https://t.co/LfHZVQTwIf

• EULAR Abstract Archive

#EULAR2020 THU0260 LESS IS BEST when it comes to steroids: Singapore 10 yr retrospect SLE study noted GCs dose is an independent predictor of mortality for hospitalized infection even when adjusted for disease activity.

#tacrolimus #prograf is non inferior to #MMF #cellcept in #lupus #nephritis induction. We’ve been doing it for years but great to see some solid RCT data behind this. #rheumatology #SLE #autoimmune https://t.co/CblD4GaXCp

• https://twitter.com/ard_bmj/status/1265674753781751813